Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies?
|
|
- Percival Gardner
- 6 years ago
- Views:
Transcription
1 Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Should There be Further Efficacy Testing of T-T cell Based Vaccines that do not Induce Broadly Neutralizing Antibodies? International AIDS Vaccine 2008 Conference Cape Town South Africa Gary J. Nabel M.D., Ph.D. Vaccine Research Center NIAID,NIH October 15, 2008
2 What Do We Want from an AIDS Vaccine? 1. Prevent infection (acquisition) 2. Prolong survival and/or time to treatment 3. Decrease transmission
3 What Do We Want from an AIDS Vaccine? 1. Prevent infection (acquisition) 2. Prolong survival and/or time to treatment 3. Decrease transmission
4 How Might a Vaccine Prevent Infection? Hypothesis: Virus infection in a susceptible individual can be prevented through the induction of a neutralizing antibody response or T cell response (direct cytolysis or cytokine secretion) at the site of entry and dissemination.
5 How Might a Vaccine Prevent Infection? Scenario 1: No Immune Protection Viral Load Time (months
6 How Might a Vaccine Prevent Infection? Scenario 2: Broadly Neutralizing Antibodies Viral Load Time (months
7 How Might a Vaccine Prevent Infection? Scenario 3: Highly Effective T Cell Vaccine Viral Load CD8 CTL Time (months -
8 How Might a Vaccine Prevent Infection? Scenario 4: Partially Effective nab Response Viral Load Time (months
9 How Might a Vaccine Prevent Infection? Scenario 5: Partially Effective nab and T Cells CD8 CTL CD8 CTL Viral Load Time (months
10 Can T Cells Prevent HIV Infection? 1. Previous studies of T cell vaccines in nonhuman primates have provided proof of concept for T cell immune protection but have not modeled natural HIV infection. 2. There is emerging evidence in relevant nonhuman primate vaccine models that T cells can prevent or strongly contain viral infection.
11 Can T Cells Prevent HIV Infection? 1. Previous studies of T cell vaccines in nonhuman primates have provided proof of concept for T cell immune protection but have not modeled natural HIV infection. 2. There is emerging evidence in relevant nonhuman primate vaccine models that T cells can prevent or strongly contain viral infection.
12 Cohort of Exposed, Uninfected Rhesus Monkeys Repeated mucosal exposure SIVsmE660 doses of virus: 1:10 (6 x 10 7 copies), 1:100 (6 x 10 6 ), 1:1000 (6 x 10 5 ) 3 monkeys/dose 6 weekly intrarectal exposures Monitored: plasma SIV RNA
13 Survival advantage in vaccinated monkeys was associated with T cell response to vaccine 100 Survival % Survival P = Days Post-Challenge Control Vaccinated
14 Can T Cells Prevent HIV Infection? 1. Previous studies of T cell vaccines in nonhuman primates have provided proof of concept for T cell immune protection but have not modeled natural HIV infection. 2. There is emerging evidence in relevant nonhuman primate vaccine models that T cells can prevent or strongly contain viral infection. -David Watkins (this session-dna/rad) -Louis Picker (today-parallel Symposium 03 17:00- rhesus CMV)
15 What Do We Want from an AIDS Vaccine? 1. Prevent infection (acquisition) 2. Prolong survival and/or time to treatment 3. Decrease transmission
16 Gene insert - SIV Challenge Study Immunogens: Plasmid DNA prime/rad5 boost SIVmac239 gag/pol, SIVmac239 env Groups: 13 rhesus monkeys/group, all Mamu-A*01 negative 1) SIV gag/pol 2) SIV env 3) SIV gag/pol + SIV env 4) Control: sham DNA/empty Ad5 Challenge: 20 wks following last vaccine inoculation 50 AID SIVmac251, i.v.
17 Clinical Trials Endpoints and Study Design
18 Randomized Control Trial Enrollment Criteria Randomized Control Treatment A (Control Rx*) *May be placebo or active Rx Double Blind Treatment B (Test Rx) Ascertainment of Primary Endpoint An RCT is at the top of a pyramid of research Gina Kolata Science Times NYT Sept 30, 2008 Elliot Antman,, Harvard Medical School
19 Surrogate Endpoints Time Disease Intervention Surrogate Endpoint Viral Load CD4? True Clinical Outcome
20 Surrogate Endpoints Time Disease Intervention Surrogate Endpoint Viral Load CD4???? True Clinical Outcome 1. Infection 2. Transmission
21 Vaccine Efficacy Against Naturally Transmitted Virus Vaccine Potency Challenge Dose
22 Vaccine Efficacy Against Naturally Transmitted Virus Vaccine Potency Challenge Dose HIV
23 Vaccine Efficacy Against Naturally Transmitted Virus Vaccine Potency Challenge Dose SIV
24 Vaccine Efficacy Against Naturally Transmitted Virus Vaccine Potency Challenge Dose SIV HIV
25 Vaccine Efficacy Against Naturally Transmitted Virus Vaccine Potency Challenge Dose HIV HIV SIV
26 The Great Divide-Infection vs. Transmission Infection Trials Transmission Trials
27 Conclusions 1. Testing of T cell vaccines in human efficacy trials should continue. There is increasing evidence of their efficacy in relevant non-human primate challenge models. 2. Trials should be sufficiently large to test specific vaccine concepts and address the scientific questions related to immune correlates, viral load, and prevention of infection. 3. Priority should be placed on candidates as follows: a. Prevention of infection based on the T cell response. b. Prevention of infection in synergy with the nab response c. Functional sterilizing immunity with either of the above. 4. If a vaccine only lowers viral load in relevant NHP models, it should be considered for evaluation in a progression/transmission study. This strategy poses significant theoretical and practical challenges and should prioritized accordingly.
28 Acknowledgements George Shaw and Beatrice Hahn (UAB) Brandon Kyle CHAVI (Bart Haynes) Norm Letvin, John Mascola, Srini Rao Rick Koup, John Mascola, Barney Graham and VRC PI s
HIV and Challenges of Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV and Challenges of Vaccine Development Richard A. Koup, MD INTEREST
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationDNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationUnderstanding HIV. Transmitted/Founder Viruses. Brandon Keele SAIC-Frederick National Cancer Institute
Understanding HIV Transmission Utilizing Transmitted/Founder Viruses Brandon Keele SAIC-Frederick National Cancer Institute AIDS Vaccine 2011 15 September 2011 Overview Several years ago, the CHAVI sought
More informationNovel Heterologous Prime-Boost Vaccine Strategies for HIV. Dan Barouch April 18, 2012
Novel Heterologous Prime-Boost Vaccine Strategies for HIV Dan Barouch April 18, 2012 Desired Features of a Next Generation HIV-1 Vaccine Candidate The RV1 study suggests that an HIV-1 vaccine is possible
More informationNIAID Vaccine Research Center: A Mission to Prevent HIV Infection
NIAID Vaccine Research Center: A Mission to Prevent HIV Infection AIDS Vaccine Awareness Day 20 year anniversary May 18, 2017 Barney S. Graham, MD, PhD Deputy Director Origins of the VRC 1997 1998
More informationUniversal Influenza Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization
More informationProfessor Andrew McMichael
BHIVA AUTUMN CONFERENCE 2011 Including CHIVA Parallel Sessions Professor Andrew McMichael University of Oxford 17 18 November 2011, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationHIV Vaccines: Basic Science
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health HIV Vaccines: Basic Science Richard A. Koup, MD 6 th INTEREST Workshop
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationPreclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps
Preclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps NIAID Workshop, May 22-23, 2018 Nancy L. Haigwood, Oregon Health & Science University Mississippi baby case brought
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationCorrelates of Immunity: RV144 - Lessons Learned
Correlates of Immunity: RV144 - Lessons Learned US Military HIV Research Program (MHRP) Nelson L. Michael, MD, PhD AIDS Vaccine 2010, Atlanta GA 01 October 2010 Outline RV 144 Correlates Discovery Towards
More informationAn AIDS vaccine: Why is it so difficult?
An AIDS vaccine: Why is it so difficult? Jaap Goudsmit, MD, PhD Professor of Poverty-related Communicable Diseases, AMC Chairman of the Board CPCD CSO, Crucell Holland BV An AIDS vaccine: Why is it so
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationThe Rational Design of an AIDS Vaccine
Leading Edge Essay The Rational Design of an AIDS Vaccine Daniel C. Douek, 1 Peter D. Kwong, 1 and Gary J. Nabel 1, * 1 Vaccine Research Center, NIAID, National Institutes of Health, Room 4502, Building
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More informationImmunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group
report Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group John Mascola, C Richter King & Ralph Steinman on behalf of a Working Group convened by the Global HIV
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationHIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationStrategies for an HIV vaccine
Strategies for an HIV vaccine Norman L. Letvin J Clin Invest. 2002;110(1):15-27. https://doi.org/10.1172/jci15985. Perspective The development of an HIV vaccine poses an unprecedented challenge to the
More informationRationale for therapy at PHI
Rationale for therapy at PHI Immunological: Interfere with pathogenesis Preserve HIV-specific CD4+ T-help Reduce T-cell activation Virological: Prevent or reduce seeding of reservoirs Affect viral set
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationWhat is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationQuestions and answers: HVTN 084 vaccine trial
1. What is the HVTN 084 trial? Questions and answers: HVTN 084 vaccine trial Version 2 Last updated December 2, 2010 HVTN 084 is the name of a clinical trial to test the safety of 2 experimental HIV vaccines.
More informationHIV An bodies Frequently Cross- React with Intes nal Microbiota An gens. Tony Moody Duke Human Vaccine Ins tute Duke University 8 April 2015
HIV An bodies Frequently Cross- React with Intes nal Microbiota An gens Tony Moody Duke Human Vaccine Ins tute Duke University 8 April 2015 Commensal Bacteria and the Immune System The intes ne is home
More informationTrials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference April, 2016
Trials & Tribulations: on the way to cure: where do HIV Vaccines fit in? Glenda Gray SA HIV Clinicians Society Conference 2016 13-16 April, 2016 Scope Rationale for an HIV vaccine RV144 study in Thailand
More informationLow-Dose Rectal Inoculation of Rhesus Macaques by SIVsmE660 or SIVmac251 Recapitulates Human Mucosal Infection by HIV-1
Low-Dose Rectal Inoculation of Rhesus Macaques by SIVsmE660 or SIVmac251 Recapitulates Human Mucosal Infection by HIV-1 The Harvard community has made this article openly available. Please share how this
More informationA global approach to HIV-1 vaccine development
A global approach to HIV-1 vaccine development The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed
More informationFrom Antibody to Vaccine a Tale of Structural Biology and Epitope Scaffolds
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services From Antibody to Vaccine a Tale
More informationHVTN Laboratory Program: Immunogenicity and Research Assays
HVTN Laboratory Program: Immunogenicity and Research Assays Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali,
More informationSUPPLEMENTARY INFORMATION
` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationFostering Clinical Development for HIV-1 Vaccine
W Fostering Clinical Development for HIV-1 Vaccine Ravimiarenduse alane seminar 9. oktoobril Tallinnas Mart Ustav, PhD CSO, SVP 1 FIT Biotech Founded in 1995 Operations in Tampere, Finland and Tartu, Estonia
More informationHIV/Sexual Health Clinical Education Session
HIV/Sexual Health Clinical Education Session http://courses.ashm.org.au/hiv/hiv-sexual-health-clinical-education-session/ About These Slide These slides may not be published, posted online, or used in
More informationPower to Detect the Effects of HIV Vaccination in Repeated Low-Dose Challenge Experiments
BRIEF REPORT Power to Detect the Effects of HIV Vaccination in Repeated Low-Dose Challenge Experiments Michael G. Hudgens, 1 Peter B. Gilbert, 2 John R. Mascola, 3 Chih-Da Wu, 1 Dan H. Barouch, 4 and Steven
More informationNovel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants
Office of AIDS Research Novel Vaccine Products for Planned Phase I Immunogenicity Studies in Infants L. Jean Patterson, PhD Office of AIDS Research, NIH February 7, 2017 Office of AIDS Research OAR Responsibilities
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationNIH Public Access Author Manuscript Nat Rev Microbiol. Author manuscript; available in PMC 2014 November 19.
NIH Public Access Author Manuscript Published in final edited form as: Nat Rev Microbiol. 2014 November ; 12(11): 765 771. doi:10.1038/nrmicro3360. Novel vaccine vectors for HIV-1 Dan H. Barouch and Center
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationSupplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants
Supplementary information Early development of broad neutralizing antibodies in HIV-1 infected infants Leslie Goo, Vrasha Chohan, Ruth Nduati, Julie Overbaugh Supplementary Figure 1. Neutralization profile
More informationNovel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Novel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques Gregory
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationFUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
More informationNIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in
More informationMicro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people
Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationComments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of Our forward looking
EBOLA HIV January 2015 Comments made today contain forward looking statements as described under the Private Securities Litigation Reform Act of 1995. Our forward looking statements represent our current
More informationHIV: RV 144 prime boost HIV vaccine efficacy study
HIV: RV 144 prime boost HIV vaccine efficacy study Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research
More informationCent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - France
Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux «Les Pensières» Fondation Mérieux Conference Center Veyrier du Lac - October 6 to 8, 2017 Steering Committee Members Françoise Barré-Sinoussi
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More informationNew Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS. Dublin, Ireland. June 24, AIDS Vaccines.
New Preventive Technology: Providing New Options to Stop the Spread of HIV/AIDS Dublin, Ireland June 24, 2004 AIDS Vaccines - An R&D Briefing This paper has been prepared by the International AIDS Vaccine
More informationAdjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus
ARTICLE Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus Marcin Kwissa, 1 Rama R. Amara, 1,2 Harriet L. Robinson,
More informationAntibody Dependent Cellular Cytotxic activity: Past and Future. Guido Ferrari, M.D. Duke University Medical Center
Antibody Dependent Cellular Cytotxic activity: Past and Future Guido Ferrari, M.D. Duke University Medical Center Mechanism of Antibody Dependent Cellular Cytotoxicity (ADCC) ADCC Effector Cells (NK, monocytes/macrophages,
More informationCD40L-Adjuvanted DNA/MVA SIV Vaccine Enhances Protection. Against Neutralization Resistant Mucosal SIV Infection
JVI Accepted Manuscript Posted Online 4 February 2015 J. Virol. doi:10.1128/jvi.03527-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 CD40L-Adjuvanted DNA/MVA SIV Vaccine
More informationIt has been 25 years since HIV-1 was identified as the causative
Vol 4j2 October 8jdoi:.38/nature732 Challenges in the development of an HIV-1 vaccine Dan H. Barouch 1 The development of a safe and effective human immunodeficiency virus (HIV)-1 vaccine is a critically
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationCent Gardes Conference: HIV Vaccines. Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - France
Cent Gardes Conference: HIV Vaccines Organized by Fondation Mérieux Les Pensières Center for Global Health Veyrier du Lac - October 6th to 8th, 2017 Steering Committee Members Françoise Barré-Sinoussi
More informationProgress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH. Division of Infectious Diseases Columbia University Medical Center
Progress in HIV Vaccine Development Magdalena Sobieszczyk, MD, MPH Division of Infectious Diseases Columbia University Medical Center 1 Outline A short history of HIV vaccine design and development Describe
More informationThird Env Manufacturing Workshop July 20 21, July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program
Third Env Manufacturing Workshop July 20 21, 2017 July 20, 2017 Mary Marovich, M.D. Director, Vaccine Research Program Presentation Outline Importance and Impact of an HIV Vaccine DAIDS/VRP Programmatic
More informationHIV/AIDS: vaccines and alternate strategies for treatment and prevention
Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Online Meeting Report HIV/AIDS: vaccines and alternate strategies for treatment and prevention Yegor Voronin 1 and Sanjay
More informationTrial Collaborators Start Date* Sites Stage HVTN BMGF IPPOX EuroVacc GSID. HVTN DAIDS GSK Sanofi Jun 2017
Ongoing s:, In, Health/AESI Contact(s) 096/EV04 106 107 108 110 A phase 1 double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationREGULATORY PATHWAYS AND CLINICAL TRIAL DESIGN FOR LONG-ACTING PrEP
REGULATORY PATHWAYS AND CLINICAL TRIAL DESIGN FOR LONG-ACTING PrEP PERSPECTIVES FROM A THEMATIC ROUNDTABLE ORGANIZED BY THE IAS INDUSTRY LIAISON FORUM BACKGROUND Since the first Phase III trials eight
More informationCurrent State of HIV Vaccine Development
Current State of HIV Vaccine Development Sandhya Vasan, MD US Military HIV Research Program Henry M. Jackson Foundation Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand AVAC HVAD
More informationA centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys Sampa Santra, Bette T. Korber, Mark Muldoon, Dan H. Barouch, Gary J. Nabel, Feng Gao, Beatrice
More informationDevelopment of Rectal Microbicides
Development of Rectal Microbicides Ian McGowan MD PhD FRCP Magee Womens Research Institute University of Pittsburgh, USA Overview Rationale for rectal microbicide development Preclinical development of
More informationHigher priming doses enhance HIV-specific humoral but not cellular. responses in a randomized, double-blind phase Ib clinical trial of
Higher priming doses enhance HIV-specific humoral but not cellular responses in a randomized, double-blind phase Ib clinical trial of preventive HIV-1 vaccines Pierre-Alexandre Bart a,b, Yunda Huang c,
More informationThe Struggle with Infectious Disease. Lecture 6
The Struggle with Infectious Disease Lecture 6 HIV/AIDS It is generally believed that: Human Immunodeficiency Virus --------- causes ------------- Acquired Immunodeficiency Syndrome History of HIV HIV
More informationOngoing HVTN Trials (Enrolling, In Follow-up, and in Long Term Follow-up)
Ongoing HVTN Trials (, In, and in ) HVTN 085 90 HVTN VRC rad5 multiclade 02/2012 Boston - Brigham; Chicago; Nashville; New York - NYBC; New York - NYBC - Bronx; Philadelphia; Rochester; San Francisco;
More informationChallenges in Designing HIV Env Immunogens for Developing a Vaccine
b514_chapter-13.qxd 12/4/2007 3:39 PM Page 327 Chapter 13 Challenges in Designing HIV Env Immunogens for Developing a Vaccine Indresh K. Srivastava* and R. Holland Cheng Summary HIV continues to be a major
More informationReceived 29 August 2002/Accepted 3 December 2002
JOURNAL OF VIROLOGY, Mar. 2003, p. 3099 3118 Vol. 77, No. 5 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.5.3099 3118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Simian-Human
More informationStatistical Science Issues in HIV Vaccine Trials: Part I
Statistical Science Issues in HIV Vaccine Trials: Part I 1 2 Outline 1. Study population 2. Criteria for selecting a vaccine for efficacy testing 3. Measuring effects of vaccination - biological markers
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationAn Evaluation of Prescreen Recruitment Data: Enrolling Racial/Ethnic Minorities in Phase I HIV Vaccine Clinical Trials
An Evaluation of Prescreen Recruitment Data: Enrolling Racial/Ethnic Minorities in Phase I HIV Vaccine Clinical Trials Yesenia Merino, CCRC; Diane R. Johnson, MPH; Nina Berkowitz; Olga Vasilenko, MS, CCRP;
More informationUpdate on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationHIV-1 Vaccine Development: Recent Advances in the CTL Platform Spotty Business ACCEPTED
JVI Accepts, published online ahead of print on 7 November 2007 J. Virol. doi:10.1128/jvi.01634-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationCorrelates of Vaccine-induced Immunity
Correlates of Vaccine-induced Immunity by 9/22/2010 10:42 AM Annecy Correlates 2010 Stanley A. Plotkin References: 1) Plotkin SA. 2001. Immunologic correlates of protection induced by vaccination. Ped.
More informationHIV Basics: Pathogenesis
HIV Basics: Pathogenesis Michael Saag, MD, FIDSA University of Alabama, Birmingham Director, Center for AIDS Research ACTHIV 2011: A State-of-the-Science Conference for Frontline Health Professionals Learning
More informationDynamics of lentiviral infection in vivo in the absence of adaptive immune responses
Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses Elissa J. Schwartz Associate Professor School of Biological Sciences Department of Mathematics & Statistics Washington
More informationVIR-2020: a CMV-based vaccine candidate for TB Aurelio Bonavia
VIR-2020: a CMV-based vaccine candidate for TB Aurelio Bonavia February 21, 2018, TB Global Forum, New Delhi, India INFECTIOUS DISEASES Massive Unmet Need 2,000,000,000 260,000,000 37,000,000 2,000,000
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
More informationPart One Immunology and Vaccination Strategies for AIDS and TB
Part One Immunology and Vaccination Strategies for AIDS and TB AIDS and Tuberculosis: A Deadly Liaison. Edited by Stefan H.E. Kaufmann and Bruce D. Walker Copyright Ó 2009 WILEY-VCH Verlag GmbH & Co. KGaA,
More informationIs an HIV Vaccine Possible?
304 BJID 2009; 13 (August) Is an HIV Vaccine Possible? Nancy A. Wilson 1,2 and David I. Watkins 1,2 1 Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; 2 Wisconsin National
More informationX/01/$ DOI: /JVI Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF VIROLOGY, Apr. 2001, p. 3753 3765 Vol. 75, No. 8 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.8.3753 3765.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Route of Simian
More informationMTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012
MTN-020 and IPM 027 and the MTN-020 DSMB Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 Developing a range of options for antiretroviral-based HIV prevention Pill
More information